Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHN7
- Development stage
- Preclinical
- Lead developer
- Henan Medical University
01
Overview
SHN7: sourced facts only. name: "Moreover, SHN7 adequately inhibited HDAC1 (IC50 = 30 nM) and HDAC6 (IC50 = 10 nM), showed an excellent reduction rate by NQO1 (kcat/Km = 5.80 × 106 M-1 s-1), and bound to STAT3 with high binding affinity (KD = 8.9 μM)." [PMID:42341572]; target: "Moreover, SHN7 adequately inhibited HDAC1 (IC50 = 30 nM) and HDAC6 (IC50 = 10 nM), showed an excellent reduction rate by NQO1 (kcat/Km = 5.80 × 106 M-1 s-1), and bound to STAT3 with high binding affinity (KD = 8.9 μM)." [PMID:42341572]; target: "Moreover, SHN7 adequately inhibited HDAC1 (IC50 = 30 nM) and HDAC6 (IC50 = 10 nM), showed an excellent reduction rate by NQO1 (kcat/Km = 5.80 × 106 M-1 s-1), and bound to STAT3 with high binding affinity (KD = 8.9 μM)." [PMID:42341572]; target: "Moreover, SHN7 adequately inhibited HDAC1 (IC50 = 30 nM) and HDAC6 (IC50 = 10 nM), showed an excellent reduction rate by NQO1 (kcat/Km = 5.80 × 106 M-1 s-1), and bound to STAT3 with high binding affinity (KD = 8.9 μM)." [PMID:42341572]; developer: "School of Pharmacy, Henan Medical University, Xinxiang 453003, China." [PMID:42341572]; stage: "Notably, SHN7 exerted strong in vivo anti-tumor effects relative to napabucasin and SAHA, with minimal toxic effects." [PMID:42341572]
02
Targets
HDAC1 (Histone Deacetylase 1)HDAC6 (Histone deacetylase 6)STAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on SHN7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHN7.